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Abstract 
Folate receptor alpha is a membrane-bound protein displaying high affinity for folic acid.  
This receptor is believed to serve as a receptor-mediated transport system of folic acid into 
cancer and cells associated with inflammation.  Interesting, most normal cells in the body have 
little if no high affinity folate receptor alpha.  Based on these attributes, folate based drug 
delivery, imaging systems, and diagnostic systems are in several stages of development 
worldwide.[1-3]  
Numerous methods have been explored in the literature in an attempt to detect low levels 
of free folate receptor and/or rare circulating cancer cells [4, 5].  In an attempt to further exploit 
these systems, we are currently exploring the use of a proprietary folate-fluorescein-PEG-biotin 
(FFPB) capture ligand synthesized by Dr. Walter Henne.  In this current project, we have 
successfully purified and characterized FFPB capture ligand, which has been incorporated into a 
secondary detection scheme of captured folate receptor positive cells utilizing fluorescein 
microscopy.  The inexpensive and previously produced folate probe was substituted for the more 
costly and cumbersome antibody based ligands that are typically used for this method.  This 
method significantly reduces false positive events associated with non-specific binding and 
capture of non-targeted cells (a problem associated with the aforementioned affinity capture 
protocols). 
 
 
6 
 
Introduction 
Folate 
Folic acid (Figure 1) is an essential vitamin of the human diet due to the inability of 
mammals to synthesize folates de novo[6].  Folic acid, which occurs naturally as folate, is vital 
for the synthesis of multiple amino acids as well as nucleic acids [7, 8].  Folate vitamin is a 
water-soluble organic molecule with relatively low molecular weight (MW = 441.4 Da) [2].  
Dietary folate has been studied and applied in many areas including, but not limited to its role as 
a dietary antianemia factor, cofactor in one-carbon metabolism, role of folate coenzymes in the 
synthesis of DNA precursors, and antiproliferative/antimicrobial agents[6].  Due to the 
importance of folate and the absence of synthesis, all mammalian cells contain at least one folate 
internalization pathway[9], which can be associated with the folate receptor (FR) or small 
membrane bound channel proteins[10].   
The FR is classified as a glycosylphosphatidylinositol-anchored glycoprotein (GPI) with 
a high affinity (KD<10-9 M) for folic acid and the physiologic circulating form of the reduced 
folate vitamin, N5-methyltetrahydrofolate [11-13].  GPI anchors have a highly conserved 
common core structure, but considerable variability can be found in the side chains and lipid 
moieties of these proteins[7, 14, 15]  FR exists in multiple isoforms with FR-α and FR-β being of 
particular interest as they have shown upregulation on both cancer cells and activated 
macrophages[1].  Due to most normal tissue virtually lacking FR[10], folate transport into 
nonmalignant adult cells relies heavily on transmembrane channel protein transportation, 
reduced-folate carrier, of the relatively small molecular weight N5-methyltetrahydrofolate [10, 
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16, 17].  The FR, unlike channel transport, relies on a process of receptor-mediated endocytosis 
for cellular internalization and therefore added ability to transport larger molecules into the cell, 
illustration of which can be found in Figure 2[1, 18, 19].  Combining the upregulation of FR on 
certain detrimental cell types and most healthy cells lacking substantial FR expression, the FR 
has become an attractive candidate for a multitude of targeted agents.  
Primarily of interest are the FR-α and FR-β isoforms due to the upregulation on various 
carcinomas and activated macrophages[1].  Cancers found to primarily upregulate FR-α include 
ovarian, lung, breast, kidney, brain, endometrial, colon, hematopoietic cells of myelongenous 
origin[1, 9], cervical, renal, nasopharyngeal[20], and mesothelioma[18].  In addition, FR 
expression may increase further with stage progression of various cancers including ovarian 
carcinomas [9, 21].  FR-β is present on activated macrophages, but not on their quiescent or 
resting counterparts[1] and therefore has promise concerning such diseases as rheumatoid 
arthritis, Crohn’s disease, psoriasis, ulcerative colitis, sarcoidosis, pulmonary fibrosis, 
atherosclerosis, systemic lupus erythematosis, multiple sclerosis, glomerulonoephritis, organ 
transplant rejection[9], diabetes, osteoarthritis[1], and leukemia[10].   
With the aforementioned carcinomas and diseases associated with upregulation of FR, 
many areas of research have utilized FR for targeted therapies and pharmaceutical agents.  FR as 
a tumor-specific ligand with various covalently attached therapeutic agents has received much 
attention in the areas of imaging, drug delivery, and immunotherapies [1, 22].  Specific examples 
of these are radiopharmaceuticals, protein toxins, chemotherapeutic drugs, magnetic resonance 
imaging (MRI) contrast agents, fluorescent dyes, immunotherapeutic agents, neutron capture 
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therapeutic agents, gene therapy vectors, oligonucleotides (including small interfering RNA 
(siRNA)), liposomes with entrapped drugs, brain tumor nanocarriers, and enzyme constructs for 
prodrug therapy[1, 10, 12, 20, 22-29]. 
Affinity Capture 
Traditional methodologies for cell separation involve various forms of centrifugation 
and/or filtration.  These techniques, while useful, have many drawbacks including low specificity 
without costly instrumentation development[30], high levels of sheer force leading to decreased 
number of active cells post separation, costly consumables, and multiple time consuming steps 
when dealing with complex matrices, such as whole blood[31].  Modern techniques have been 
developed which utilize paramagnetic properties of metals.  These techniques rely on the cells of 
interest containing either intrinsic magnetic properties or are tagged with a magnetic label for 
separation (for a thorough review of magnetic cell separation techniques see reference 28).  Of 
the two techniques, cell types containing intrinsic magnetic properties are extremely limited with 
red blood cells (erythrocytes) and magnetotactic bacteria being the only cell types existing in 
nature.  Magnetic labeling, however, is limited only by the existence of an appropriate cell 
surface target and some form of affinity ligand with bound paramagnetic particle.  After 
successful attachment of paramagnetic particles, cells can then be separated using either flow-
through or batch magnetic separators.   
Flow-through magnetic separators have the advantage of typically high throughput, but 
are usually more expensive and require large sample volumes.  Batch separators are preferred 
due to commercially available laboratory scale magnetic separators.  Batch separators typically 
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consist of racks with tubes and a strong permanent rare earth magnet.  Various forms of batch 
separators are designed to accommodate volumes ranging approximately from 5 µL to 1000 
mL[31].   
Magnetic labeling of cells is performed using two predominant methods consisting of 
direct or indirect methods.  In the direct method, magnetic particles and ligand are coupled and 
then added directly to sample containing target cells.  Incubation allows for direct binding of the 
magnetic particles, which can later be isolated using a magnetic separator.  The indirect method 
relies on first incubating cells with primary affinity ligand followed by removal of excess 
unbound affinity ligand.  Magnetic particles with an immobilized secondary affinity ligand 
targeted for the primary affinity ligand are added, will bind with target cells, and then can be 
isolated magnetically.  While the direct method typically requires less incubation time, the 
indirect method generally is more efficient with higher purity due to “free” primary affinity 
ligand more readily finding their cell surface target[31, 32].  Many examples of selective 
magnetic separation targeting human cells subsets include, but are not limited to bone marrow 
cancers, B lymphocytes, endothelial cells, granulocytes, hematopoietic progenitor cells, 
Langerhans cells, leukocytes, monocytes, natural killer cells, reticulocytes, T-lymphocytes, 
spermatozoa[31], and breast cancer cells[33]. 
In this report, we describe the development of a folate fluorescein PEG biotin (FFPB), 
Figure 3, capture ligand that can be used for the indirect capture and detection of folate receptor 
positive cancer cells.  By incorporating the fluorescein fluorophore into the folate PEG biotin 
chain, cancer cells can be captured followed by assessment and confirmation via a secondary 
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detection scheme (i.e. fluorescein microscopy or flow cytometry).  This method significantly 
reduces false positive events associated with non-specific binding and capture of non-targeted 
cells (a problem associated with affinity capture protocols). 
 
Materials & Methods 
Preparative HPLC of Folate-Fluorescein-PEG-Biotin 
The proprietary Folate-Fluorescein-PEG -Biotin molecule prepared by Dr. Walter Henne 
was purified with a Hewlett Packard, series 1050 HPLC equipped with a Diode array detector 
and ChemStation software. 
The following instrument and method parameters were utilized: 
• Column: Rigel 5µm C18 10X250mm from Stellar Phases Inc. (cat.#: 5C18-10-250) 
• Solvent A: 10 mM Ammonium Bicarbonate Buffer (NH4HCO3) 
• Solvent B: Acetonitrile (ACN) 
• Flow Rate: 1ml/min 
• Run Time: 60 min 
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• Gradient:  
Time (min) NH4HCO3 (%) ACN (%) 
0 99 1 
30 70 30 
35 40 60 
40 10 90 
45 10 90 
60 99 1 
LC/MS Analysis 
The purified FPFB sample was analyzed using an Agilent Technologies, 1100 series 
LC/MSD Trap XCT for identity and purity confirmation utilizing Agilent ChemStation software 
and negative ion mode. 
The following instrument and method parameters were utilized: 
• Column: Eclipse XDB C18 
• Solvent: Methanol and Water 
• Sample Preparation: 1 to 5 dilution FFPB in Acetonitrile 
• Injected Sample Volume: 5µl 
• Flow Rate: 0.5ml 
• Scan Range: 500-1500 m/z 
• Gradient: 
Time (min) Methanol (%) 
0 30 
1 50 
2 70 
3 90 
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Preliminary FFPB Structure Modeling 
• Preliminary Modeling was performed using Hyperchem 8.0.3 with Amber setting and a 
hydrated environment. 
Capture of FR-α Cells with Streptavidin Coated Magnetic Beads 
• MagnabindTM Streptavidin from Thermo Scientific: Capacity- 2µg Biotin/ml resin with 
approximately 1.4µm average diameter 
• Cells: L1210 mouse murine leukemia from Purdue University. 
• RPMI Medium 1640 from Gibco/Invitrogen: [+]L-Glutamine, [+]Phenol Red, [-]Folic acid 
• Phosphate Buffered Saline: 1X from Cellgro (Mediatech, Inc) without Calcium and 
Magnesium, Cat. No. 21-040-CV 
 
• Assay Sequence 
Approximately one million L1210 mouse murine leukemia cells were incubated 
with 100 nM Folate-Fluorescein-PEG-Biotin (FFPB) bridging ligand for 30 minutes 
at 37°C.  The sample was then centrifuged at 1000 g for 45 seconds.  Supernatant was 
removed and cells were washed with RPMI Medium 1640 to remove unbound FFPB.  
Washing procedure was performed in triplicate.  After final wash, the supernatant was 
again removed.  Cells were then resuspended in cell media and incubated with 15 µL of 
MagnabindTM Streptavidin beads for 30 minutes at room temperature with intermittent 
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gentle swirling by hand.  Captured cells were then isolated by utilizing a batch 
magnetic separator.  Eppendorf tubes were placed in magnetic stand, supernatant 
removed, and cells washed with cell media to remove untargeted/uncaptured cells.  
Isolation procedure was performed in triplicate.   
A control study was performed using approximately one million L1210 mouse 
murine leukemia cells were incubated with 15 µL of MagnabindTM Streptavidin beads 
for 30 minutes at room temperature with intermittent gentle swirling by hand to 
evaluate nonspecific binding events.  Captured cells were then isolated by utilizing a 
batch magnetic separator.  Eppendorf tubes were placed in magnetic stand, supernatant 
removed, and cells washed with cell media to remove untargeted/uncaptured cells.  
Isolation procedure was performed in triplicate. 
Isolated cells from both FFPB assisted and non-FFPB assisted studies were 
observed utilizing light microscopy and fluorescent microscopy with a fluorescein 
filter. 
 
Results and Discussion 
The resultant chromatogram from preparative analysis of FFPB using a Hewlett Packard, 
series 1050 HPLC, Figure 4, resulted in a sharp, high intensity peak with a retention time of 
14.74 minutes and a spurious peak at approximately 4.66 minutes when monitored at a 
wavelength of 280 nm.  Monitoring at 365 nm gave rise to a well-defined peak attributed to 
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folate with a retention time of 14.74 minutes and a low intensity peak at 4.66 minutes attributed 
to column carrier over contamination (Figure 5). 
Further analysis was performed using the diode array detector to confirm the 
aforementioned folate peak with a 14.74 minute retention time.  The diode array spectrum gave 
rise to a typical double event with maximum absorbancies at approximately 280 and 360 nm, 
which is indicative of folate (Figure 6).  In addition, a typical peak associated with fluorescein 
was observed at approximately 480-490 nm.  Combining data from HPLC and DAD leads to 
confirmation of a relatively pure compound. 
The purified FFPB was collected and analyzed using an Agilent Technologies, 1100 
series LC/MSD Trap XCT for identity confirmation with aforementioned parameters.  The LC 
chromatogram, Figure 7, gave rise to one prominent peak with a retention time of 5.3-6.0 
minutes, assigned as FFPB, and a spurious peak due to column carryover between 6.1-6.5 
minutes (Figure 7).  Mass spectral analysis between 5.3-6.0 minutes yielded monoisotopic peaks 
for both the singly and doubly charged molecular ion forms of  FFPB at m/z = 1385 and m/z = 
692, respectively(Figure 8).  These findings are consistent with the calculated FFPB molecular 
mass, 1386.6 Da, following a respective M* – 1 and M** – 1 scheme for the molecular ion 
species.  Further, the doubly charged base peak was the predominant species observed and 
consistent with similar compounds. 
A preliminary computer modeling was conducted using Hyperchem in a hydrated form.  
Data from this modeling supports the idea that addition of the fluorescein fluorophore does not 
appear to interfere with biotin or folic acid (Figure 9).  While alteration of binding has been 
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noted by previous work using conjugates with shorter PEG, preliminary modeling suggests 
sufficient PEG length for minimization of binding interference. 
We performed a cell capture studies with and without FFPB binding ligand followed by 
light and fluorescent microscopy.  Select images can be found in Figure 10.  Cells captured using 
FFPB binding ligand were observed to have a higher level of binding, Figure 10A, when 
compared to control cells experiencing non-specific binding and subsequent capture when 
incubated solely with MagnabindTM Streptavidin beads, Figure 10C, under light microscopy.  
Fluorescein microscopy was utilized to assess and confirmed successful FFPB capture in 
comparison to that of non-specific binding, therefore lacking fluorescein (Figures 10B and 10D 
respectively). 
 
Conclusion 
Folate fluorescein PEG biotin capture ligand has been successfully developed for 
isolation and detection of folate receptor positive cancer cells via an indirect Immunomagnetic 
assay.  Characterization of the proprietary FFPB yielded a high purity compound with confirmed 
components of folate and fluorescein accompanied by structural confirmation via mass 
spectrometry.  Preliminary structural modeling gave promise to the lack of fluorescein binding 
hindrance for both folate and streptavidin.  Lastly, incorporation of a fluorescein fluorophore 
enabled assessment of specific and non-specific cell capture using secondary detection via 
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fluorescein microscopy.  Overall, FFPB was shown to be a promising tool for the detection, 
capture, assessment, and confirmation of folate receptor positive cancer cells in vitro.   
 
Future Studies 
 Further study of FFPB in the realm of characterization should include additional 
structural confirmation utilizing 1H-NMR, 13C-NMR, X-ray diffraction, positive ion-mode mass 
spectrometry, differential scanning calorimetry, and thermogravimetric analysis.  Due to the 
success of FFPB with regards to cell capture, of interest are techniques based on using a 
handheld cytometer for fast comparison of relative captured cells on not only a qualitative level, 
but also quantitative.  Lastly, while this study has proved successful, assay optimization and use 
with complex whole blood samples would be of much interest moving forward. 
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